Polymorphisms of α1-antitrypsin and Interleukin-6 genes and the progression of hepatic cirrhosis in patients with a hepatitis C virus infection

Parameters	Control (n = 100)	Chronic Hepatitis Patients (n= 85)	Cirrhotic Patients (n = 65)
Sexes	M: 45; F: 55	M: 55; F: 30	M: 35; F: 30
Age (years ± SE)	33.10 ± 1.83	38.88 ± 1.92	38.92 ± 2.36
Serum ALT (IU/mL)	30.00 ± 1.34	83.53 ± 16.03 significant values (p <0.05) when compared to the control group.	110.00 ± 14.63 significant values (p <0.05) when compared to the control group.
Serum AST (IU/mL)	30.20 ± 1.36	76.76 ± 11.07 significant values (p <0.05) when compared to the control group.	172.92 ± 27.76 significant values (p <0.05) when compared to the control group. , significant values (p <0.05) between chronic hepatitis and cirrhotic patients.
Serum ALP (IU/mL)	43.65 ± 1.69	113.71 ± 6.51 significant values (p <0.05) when compared to the control group.	119.85 ± 9.49 significant values (p <0.05) when compared to the control group.
Total bilirubin (mg/dL)	0.75 ± 0.045	0.92 ± 0.098	1.09 ± 0.14 significant values (p <0.05) when compared to the control group.
Direct bilirubin (mg/dL)	0.15 ± 0.01	0.25 ± 0.06	0.28 ± 0.05
Albumin (g/dL)	3.85 ± 0.05	3.69 ± 0.05	3.21 ± 0.11 significant values (p <0.05) when compared to the control group. , significant values (p <0.05) between chronic hepatitis and cirrhotic patients.
Prothrombin time (seconds)	11.19 ± 0.14	11.53 ± 0.19	13.46 ± 0.51 significant values (p <0.05) when compared to the control group. , significant values (p <0.05) between chronic hepatitis and cirrhotic patients.
AFP (ng/mL)	5.86 ± 0.45	8.76 ± 0.55	27.38 ± 6.91 significant values (p <0.05) when compared to the control group. , significant values (p <0.05) between chronic hepatitis and cirrhotic patients.
Fibrosis score (1-6)	—	1.94 ± 0.18	4.46 ± 0.14 significant values (p <0.05) when compared to the control group.

The single nucleotide polymorphism pattern of the A1TAT gene in the control group, chronic hepatitis patients and cirrhotic patients_

Parameters	Control Group n (%)	Chronic Hepatitis Patients n (%)	Cirrhotic Patients n (%)
Genotypes:
MM	85 (85.0)	40 (47.0)	35 (53.8) significant values (p <0.05) when compared to the control group.
MS	10 (10.0)	30 (35.3)	15 (23.1)
MZ	5 (5.0)	5 (5.9)	0 (0.0)
ZZ	0 (0.0)	10 (11.8)	0 (0.0)
SS	0 (0.0	0 (0.0)	15 (23.1)
Alleles:
M	185 (92.5)	115 (67.6)	85 (56.4) significant values (p <0.05) when compared to the control group.
S	10 (5.0)	30 (17.6)	45 (34.6) significant values (p <0.05) when compared to the control group.
Z	5 (2.5)	25 (14.7)	0 (0.0)

The biochemical parameters within different A1AT genotypes in the control group, chronic hepatitis patients and cirrhotic patients_

Parameters	Control Group		Chronic Hepatitis Patients			Cirrhotic Patients
	MM	MS+MZ	MM	MS	MZ+ZZ	MM	MS+SS
Serum ALT (IU/mL)	30.2±1.5	28.7±2.6	65.4±6.9	67.7±13.20	163.7±80.2	87.0±80.2	176.3±43.4 significant values (p <0.05) when the MS+SS genotypes of cirrhotic patients were compared to the MM genotypes of cirrhotic patients.
Serum AST (IU/mL)	30.1±1.6	31.0±2.5	68.0±5.6	57.3±10.50	139.0±47.9 significant values (p <0.05) when the MZ+ZZ genotypes of chronic hepatitis patients were compared to the MM genotypes of chronic hepatitis patients. significant values (p <0.05) when the MZ+ZZ genotypes of chronic hepatitis patients were compared to the MS genotypes of chronic hepatitis patients.	127.7±20.1	300.7±65.9 significant values (p <0.05) when the MS+SS genotypes of cirrhotic patients were compared to the MM genotypes of cirrhotic patients.
Serum ALP (IU/mL)	44.5±1.9	38.7±0.9	109.3±7.4	115.5±5.70	122.0±34.5	114.6±10.8	130.7±34.8
Total bilirubin (mg/dL)	0.8±0.1	0.7±0.2	0.8±0.07	0.9±0.10	1.3±0.5	0.9±0.1	1.8±0.4 significant values (p <0.05) when the MS+SS genotypes of cirrhotic patients were compared to the MM genotypes of cirrhotic patients.
Direct bilirubin (mg/dL)	0.2±0.02	0.1±0.03	0.2±0.02	0.2±0.04	0.5±0.3	0.2±0.01	0.5±0.2 significant values (p <0.05) when the MS+SS genotypes of cirrhotic patients were compared to the MM genotypes of cirrhotic patients.
Albumin (g/dL)	3.8±0.05	3.9±0.2	3.7±0.1	3.7±0.10	3.6±0.03	3.3±0.1	2.7±0.1 significant values (p <0.05) when the MS+SS genotypes of cirrhotic patients were compared to the MM genotypes of cirrhotic patients.
Prothrombin time (seconds)	11.2±0.2	11.3±0.3	11.5±0.2	11.2±0.20	12.3±0.9	13.7±0.6	15.0±0.6
AFP (ng/mL)	6.0±0.5	5.0±1.0	8.6±0.9	8.7±1.00	9.3±1.0	25.6±10.3	48.3±11.2
Fibrosis score (1-6)	—	—	2.1±0.3	1.5±0.20	2.3±0.3	4.6±0.2	4.3±0.3

The single nucleotide polymorphism pattern of the IL-6 gene in the control group, chronic hepatitis patients and cirrhotic patients_

Parameters	Control Group n (%)	Chronic Hepatitis Patients n (%)	Cirrhotic Patients n (%)
Genotypes:
GG	100 (100.0)	60 (70.6)	40 (61.5) significant values (p <0.05) when compared to the control group.
GC	0 (0.0)	20 (23.5)	25 (38.5)
CC	0 (0.0)	5 (5.9)	0 (0.0)
Alleles:
G	200 (100.0)	140 (82.4)	105 (80.8)
C	0 (0.0)	30 (17.6)	25 (19.2) significant values (p <0.05) when compared to the control group.

The biochemical parameters within different IL-6 genotypes in the control group, chronic hepatitis patients and cirrhotic patients_

Parameters	Genotypes
	Control Group	Chronic Hepatitis Patients		Cirrhotic Patients
	GG	GG+GC	CC	GG	GC
Serum ALT (IU/mL)	30.00±1.34	80.75±7.09	128.10±52.91	102.63±17.87	121.80±26.81
Serum AST (IU/mL)	30.20±1.36	73.33±5.61	137.45±35.74	150.50±28.65	208.80±54.69
Serum ALP (IU/mL)	43.65±1.69	115.93±5.45	78.34±19.49	125.25±14.21	111.20±10.31
Total bilirubin (mg/dL)	0.75±0.045	0.92±0.06	0.90±0.32	1.09±0.17	1.00±0.28
Direct bilirubin (mg/dL)	0.15±0.01	0.26±0.02	0.20±0.19	0.29±0.07	0.26±0.09
Albumin (g/dL)	3.85±0.05	3.69±0.07	3.60±0.06	3.26±0.13	3.12±0.23
Prothrombin time (seconds)	11.19±0.14	11.50±0.15	12.10±0.58	14.00±0.63	12.60±0.81
AFP (ng/mL)	5.86±0.45	8.87±0.65	7.00±1.05	25.63±8.94	30.20±12.04
Fibrosis score (1-6)	—	1.93±0.23	2.00±0.32	4.50±0.19	4.40±0.24

Sprache:: Englisch

Zeitrahmen der Veröffentlichung:: 2 Hefte pro Jahr
Fachgebiete der Zeitschrift:: Medizin, Vorklinische Medizin, Grundlagenmedizin, Vorklinische Medizin, Grundlagenmedizin, andere

Zeitschrift RSS Feed

Polymorphisms of α1-antitrypsin and Interleukin-6 genes and the progression of hepatic cirrhosis in patients with a hepatitis C virus infection

T Motawi

OG Shaker

RM Hussein

M Houssen

Artikel-Kategorie: Original Article

Online veröffentlicht: 31. Dez. 2016

Seitenbereich: 35 - 44

DOI: https://doi.org/10.1515/bjmg-2016-0034

Schlüsselwörterα1 Antitrypsin (A1AT), Cirrhosis, Inter-leukin 6 (IL-6), Hepatitis C virus (HCV) infection, Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), Polymorphism

© 2016 Motawi T, Shaker OG, Hussein RM, Houssen M

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

The clinical characteristics and biochemical parameters of the control group, chronic hepatitis patients and cirrhotic patients_

The single nucleotide polymorphism pattern of the A1TAT gene in the control group, chronic hepatitis patients and cirrhotic patients_

The biochemical parameters within different A1AT genotypes in the control group, chronic hepatitis patients and cirrhotic patients_

The single nucleotide polymorphism pattern of the IL-6 gene in the control group, chronic hepatitis patients and cirrhotic patients_

The biochemical parameters within different IL-6 genotypes in the control group, chronic hepatitis patients and cirrhotic patients_

Schlüsselwörter
α1 Antitrypsin (A1AT), Cirrhosis, Inter-leukin 6 (IL-6), Hepatitis C virus (HCV) infection, Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), Polymorphism